摘要
非诺贝特作为调脂类药物,在其机制尚未明确阐释之前,目前已有大量基础研究证实其能抑制心肌肥大,对心肌肥大的临床治疗提供了广阔的视野与理论基础。综述非诺贝特在治疗心肌肥大中的可能机制,进一步了解非诺贝特在调节血脂之外的其他药理作用,对展望探讨其更深入的信号通路机制及更广的治疗前景有着重要的意义。
As lipid-regulating drug,the mechanism of fenofibrate is not clear.A large number of basic studies have been confirmed that it can inhibit myocardial hypertrophy.The clinical treatment of myocardial hypertrophy has provided a broad field of vision and theoretical basis.The treatment of fenofibrate in myocardial hypertrophy through the possible mechanism was reviewed.Further understanding of the other pharmacological effects of fenofibrate except for regulating blood lipid is needed.Further signal pathway and broader prospects are expected.
出处
《中国临床药理学与治疗学》
CAS
CSCD
2014年第3期356-360,共5页
Chinese Journal of Clinical Pharmacology and Therapeutics
基金
国家自然科学基金青年科学基金资助项目(81000072)
关键词
非诺贝特
心肌肥大
过氧化物酶体增殖剂激活受体α
机制
fenofibrate
myocardial hypertrophy
peroxisome proliferator activated receptorα
mechanism
